



Vaccination Against Hydatidosis: Molecular Cloning and Optimal Expression of the EG95NC⁻ Recombinant Antigen in *Escherichia coli*

M. Jazouli^{1,2,3} · M. Lightowlers² · C. G. Gauci² · K. Tadlaoui¹ · A. Belmlih¹ · M. M. Ennaji³ · M. Elharrak¹

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Abstract

Cystic echinococcosis (CE) is a widely distributed zoonosis that is highly endemic in the Mediterranean basin. The disease represents a serious public health threat and causes economic losses. The parasite life-cycle involves dogs and ruminants as definitive and intermediate hosts; humans are accidentally infected, causing serious clinical issues. Vaccination of ruminants and dog treatments represent the most efficient measures to prevent parasite transmission. The recombinant protein vaccine, EG95, has been used successfully in sheep vaccine trials against CE in several countries. In this study, we expressed the modified antigen, EG95NC-GST, in *Escherichia coli* for use as a vaccine against *Echinococcus granulosus* in ruminants. We tested three different media formulations for *E. coli* culture and established for each culture conditions for optimal levels of soluble EG95 expression. The results demonstrate that SOC and TB media provided high yields in cell density and EG95 protein expression. Purification of the recombinant protein with affinity chromatography (using FPLC) was also performed to increase the purity of the EG95NC⁻-GST antigen.

Keywords *Echinococcus granulosus* · Hydatidosis · *Escherichia coli* · Recombinant protein · Vaccine

Abbreviations

CE	Cystic echinococcosis
GST	Glutathione <i>S</i> -transferase
IPTG	Isopropyl- β -D-thiogalactoside
LB	Luria broth
TB	Terrific broth
SOC	Super broth
FPLC	Fast protein liquid chromatography
SDS-PAGE	Sodium dodecyl sulphate-polyacrylamide gel Electrophoresis

1 Background

Echinococcus granulosus is cyclophyllid cestode causative agent of cystic echinococcosis (CE) or hydatidosis, a chronic and zoonotic infection that occurs worldwide and is caused by the larval stage of the parasite [1]. It has a considerable socio-economic impact in endemic areas [1]. It is assumed that 50 million people are at risk of acquiring the disease in Asia and Africa [2]. Morocco is known as an endemic country [3]; in 2012, 5.5 per 100,000 inhabitant of CE were recorded in the country with 3% fatality [4].

M. M. Ennaji and M. Elharrak have contributed equally.

✉ M. Jazouli
m.jazouli@mci-santeanimale.com

M. Lightowlers
mwl@unimelb.edu.au

C. G. Gauci
charlesg@unimelb.edu.au

K. Tadlaoui
k.tadlaoui@mci-santeanimale.com

A. Belmlih
a.belmlih@mci-santeanimale.com

M. M. Ennaji
m.ennaji@yahoo.fr

M. Elharrak
M.Elharrak@mci-santeanimale.com

- ¹ Research and Development of Recombinant Vaccine, Multi-Chemical Industry, Lot. 157, Z I, Sud-Ouest (ERAC) B.P.: 278, 28810 Mohammedia, Morocco
- ² Molecular Parasitology Laboratory, The University of Melbourne, Princes Highway, Werribee, VIC 3030, Australia
- ³ Laboratory of Virology, Hygiene and Microbiology, Faculty of Science and Technology, University Hassan II-Casablanca, 20650 Mohammedia, Morocco

In Morocco, 22–58.8% is the infection rate in dogs depending on the region [5]. For livestock, Azlaf and Dakkak reported an infection rate of 10.6% in sheep, 1.9% in goats, 23% in cattle, 12% in camels and 17.8% in equines, mostly in the Middle Atlas (48.7% in cattle) and in the North West (37.6% in cattle and 31.6% in sheep) regions of Morocco [6] with a higher number of infections caused by the genotype G1 (96%) followed by G3 (3%) and G2 (1%) with similar rates of infection in cattle and sheep [7].

Vaccination of sheep intermediate hosts against CE is an interesting option that has evolved considerably in recent years with the development of a new recombinant vaccine [8]. A similar strategy has been tested successfully using the recombinant protein EG95 as recombinant vaccine against *Echinococcus granulosus* showing an effective protection [8–10].

EG95 has been reported to be a highly effective sheep vaccine in Australia, New Zealand, Argentina and China [9, 11, 12]. Lightowlers et al. [8] used this protein for sheep vaccination; the vaccine provided a high degree of protection (96–98%) against experimental challenge with *E. granulosus*. Using a truncated cDNA encoding the EG95 antigen (EG95NC⁻). Gauci et al. [13] succeeded in producing a plasmid construct that achieved high level expression of immunogenic protein. The vaccine may prove to be a useful tool in the control of hydatidosis in endemic areas [12, 13].

The objective of this study was to optimize production conditions of the truncated recombinant protein, EG95NC⁻, in *Escherichia coli* using three different media formulations that favour veterinary vaccine preparation.

2 Materials and Methods

2.1 Strains and Plasmids

Escherichia coli Top10F' (Invitrogen) was used as the host strain for recombinant plasmid preparation. *E. coli* BL21 DE3 (Invitrogen) was used as an expression host. The expression vector used was plasmid pGEX (GE Healthcare). The pGEX vector contains the *tac* promoter and allows expression of recombinant protein fused to the C-terminus of Glutathione *S*-transferase (GST).

2.2 Gene Synthesis and Cloning

The truncated EG95NC⁻ cDNA was synthesised with codon optimisation for procaryotic expression (Fig. 1) and cloned into *Bam*HI/*Xho*I restriction sites in the same reading frame with the GST tag in the pGEX vector. The recombinant plasmid was transformed into *E. Coli* Top10F'. The plasmid was extracted from the bacteria using the Plasmid MiniPrep DNA Extraction Kit, (Qiagen), and digested by *Bam*HI/*Xho*I

enzymes to confirm ligation of this gene into the pGEX plasmid (Fig. 2). Nucleotide sequencing was performed to confirm correct insertion of the target gene.

2.3 Expression of Recombinant EG95NC⁻-GST Protein in *E. coli*

The plasmid pGEX-EG95NC⁻ was transformed into *E. coli* BL21 (DE3). Culture of recombinant *E. coli* was performed in shake flasks. In order to provide the optimum conditions for aeration and mixing, the culture volume represented 20% of the total flask volume. Luria broth medium (LB) containing 100 µg/ml of ampicillin (Serva) was inoculated with the recombinant *E. coli* and incubated in a shaker incubator (MaxQ 4000, Thermo Scientific) at 37 °C, 200 rpm for 14 h. Cell density was measured until the OD (595 nm) reached approximately 0.8–1 unit and dilution made for the second passage at OD 0.05 in LB medium containing ampicillin 100 µg/ml, followed by incubated with shaking.

Protein expression was induced by addition of isopropyl-β-D-thiogalactoside (IPTG, Promega) at a concentration of 0.5 mM. Assessment of levels of recombinant protein expression was performed for 5 h every hour during cultivation, *E. coli* cell suspensions were centrifuged at 3500g (1-15PK; SIGMA). The culture supernatant was discarded and bacterial pellets suspended in loading buffer (Tris 50 mM, glycine 200 mM, SDS 0.1%, beta mercaptoethanol 5%, pH 8.3) and lysed in a water bath at 95 °C for 5 min before chilling on ice for SDS-PAGE analysis (Fig. 3).

2.4 Media Trials for Expression Optimization

To evaluate the EG95NC⁻ recombinant protein production, media commonly used for *E. coli* culture, were tested. Duplicate cultures were carried out in three different media induced with IPTG at 0.5 mM: Luria broth (LB), terrific broth (TB) and super broth (SOC). All media were formulated as specified in the Handbook of Microbiological Media (Atlas 1997). An overnight culture of *E. coli* BL21 (DE3) containing the pGEX-EG95NC⁻ plasmid in the three media was diluted to OD 0.05 with ampicillin. Expression kinetics were determined for all media with cell density control. Optimum cell culture conditions were selected for scale-up production of the antigen in a fermentor and affinity purification.

2.5 Purification of Recombinant Proteins by Affinity Chromatography

Pellets obtained from 2 l of the *E. coli* cultures expressing the EG95NC-GST-tagged proteins were suspended in 50 ml PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.4) supplemented with 1 mM DTT,

EG95
 QLCLILFATSVLAQEYKGMGVETRTE TPLRKHFNLTPVGSQGIRLSWEVQHLSDLKGTDISLKAVNPSDPLVYKR
 QTAKFSDGQLTIGELKPSTLYKMTVEAVKAKKTILGFTVDIE TPRAGKKESTVMTSGSAL TSAIAGVFVFCIVVLT

EG95NC-
 QEYKGMGVETRTRTETPLRKHFNLTPVGSQGIRLSWEVQHLSDLKGTDISLKAVNPSDPLVYKRQTAKFSDGQLTI
 GELKPSTLYKMTVEAVKAKKTILGFTVDIE TPRAGKKESTVMTSGSA

Fig. 1 Amino acid sequences of full EG95 gene and truncated EG95NC-gene




Fig. 2 Agarose gel electrophoresis of recombinant plasmid pGEX-EG95NC double digested with (BamHI/XhoI). Lane 1: double digestion of plasmid. Lane 2: plasmid undigested. SM: DNA size marker

10 μM EDTA + 1 mM PMSF. The cells were lysed by sonication with a MSE ultrasonic processor for 3 min, amplitude 50%. The cell extract was kept on ice during sonication. Cell debris was removed by centrifugation at 28,000g, 4 °C for 15 min. The supernatant was applied to a 0.45 μm filter.

The following purification procedures were performed using fast protein liquid chromatography (FPLC) and Akta Purifier 100 chromatography system. The columns, GST-Prep FF 16/10 (GE Healthcare) were equilibrated with five column volumes (CV) of PBS, pH 7.4 and the sample was applied to the column. The column was washed with 5 CV of PBS and the fusion protein was eluted with a gradient using seven CV of Tris-HCl, pH 8.0 including 10 mM reduced glutathione. The purity of eluted proteins was analyzed by SDS-PAGE.

2.6 SDS-PAGE Analysis of Recombinant Protein

Proteins were resolved by SDS-PAGE, (10% w/v separating gel) under reducing conditions using the discontinuous buffer system [14] and a Protean II vertical electrophoresis system (Bio-Rad Laboratories, CA, USA). Protein calibration markers (broad range 2–212 kDa, Biolabs) were used




Fig. 3 SDS-PAGE analysis of *E. coli* culture samples expressing EG95NC-GST. S: sample before IPTG induction. 1–6: 1–6 h post induction with 0.5 mM IPTG. SM: protein size marker

as size standards. Proteins were visualized by staining with Coomassie brilliant blue R250 (Sigma, USA).

2.7 Protein Expression Estimation

Bovine serum albumin (BSA, Amresco) at concentrations from 2 to 25 μg/μl was loaded onto SDS-PAGE in parallel with different volumes of *E. coli* lysis products corresponding to samples obtained during culture. Gels were scanned and the percentage of the recombinant protein present in the sample was estimated and compared to BSA concentration, using GelQuant.NET (BiochemLabSolution.com). The pixel densities of the bands corresponding to BSA protein concentration were used to plot a standard curve (pixel densities vs. BSA concentration), and used to approximate the recombinant protein concentration.

2.8 Purified Protein Assay

Protein concentration was estimated using the method of Bradford [15]. A standard curve [concentration “μg” = f (absorbance at 595 nm)] was determined using five dilutions of BSA protein with a range from 1 to 25 μg/ml. The absorbance measurement at 595 nm obtained with the diluted recombinant protein dosage was used for protein quantification according to the BSA standard curve.

3 Results

3.1 Gene Synthesis and Cloning

Digested products controlled with agarose gel electrophoresis revealed a DNA band at about 370 bp (Fig. 2). Nucleotide sequencing (data not shown) results confirmed the successful construction of the recombinant expression plasmid pGEX-EG95NC.

3.2 Expression of Recombinant EG95NC⁻-GST Protein

Escherichia coli cultures expressing EG95NC⁻-GST was analyzed in SDS-PAGE showing a protein band at approximately 40 kDa, corresponding to the expected protein size. The EG95 protein expression was absent before induction with IPTG in the first lane and shows increasing yields during the induction of the culture (Fig. 3).

3.3 Expression Optimization with Culture Media

The growth rates of the recombinant bacteria cultured on three media are shown in Fig. 4. The final *E. coli* cell concentrations varied with the three media tested. The LB (Luria–Bertani) medium, although commonly used in cultivation of *E. coli* and expression of recombinant proteins [16, 17], produced the lowest final cell density comparing to SOC medium and TB medium. As shown in Fig. 4 the highest final cell density was obtained with SOC medium and simultaneously produced the highest level of EG95NC⁻-GST recombinant protein shown by highest densities of the bands compared to TB medium (Fig. 5) and LB medium (data not shown). Recombinant protein concentration was estimated using GelQuant software to be 200 mg/l from TB medium (4000 doses/l) versus 350 mg/l with SOC medium which represents 7000 doses/l (50 µg/dose as recommended by Lightowlers et al. [11]).

Fig. 4 Cell density of recombinant *E. coli* cultures using Luria broth medium (LB), terrific broth medium (TB) and super broth medium (SOC)





Fig. 5 SDS-PAGE analysis of recombinant bacteria expressing EG95NC-GST in TB and SOC medium. 1–3: 4, 5 and 6 h post induction using TB medium. 4–6: 4, 5 and 6 h post induction using SOC medium. SM: protein size marker. Arrow denotes position of the recombinant proteins

3.4 Purification and Protein Assay

The substantial increase in yield of EG95NC⁻-GST allowed scale-up of the antigen production using Fermentor with SOC medium. Following purification on a glutathione Sepharose column using FPLC, fractions containing the protein EG95NC⁻-GST (A1-B6) (Figs. 6, 7) were pooled and concentrated. This provided significant amounts of purified antigen (260 mg/l) which represents 5200 doses/l to supply large scale vaccine formulation.

4 Discussion

Cystic echinococcosis is an important zoonotic disease caused by cestodes of the genus *Echinococcus*. Recombinant vaccine EG95 provide a very practical and cost-effective prevention strategy against hydatidosis.

Achieving the goal of expression optimization to increase the quantity of produced recombinant protein using three different medium and codon optimization that




Fig. 6 Purification chromatogram of the *EG95NC-GST* protein using GSTPrep FF 16/10 column




Fig. 7 SDS-PAGE analysis of the eluted fractions. S: start material diluted 3 \times . A2–B6: eluted fractions. SM protein size marker

can improve the efficiency of protein expression, It has been reported that LB medium has no buffering system, with a low amount of carbon source, nitrogen and divalent cations which does not support growth to very high cell density [18]. Consistent with the data shown in Fig. 4, media such as TB and SOC are generally considered better for obtaining high cell densities, more rich of yeast extract and phosphate salts which is very important during recombinant protein synthesis [19, 20] with a good buffering capacity to prevent pH fluctuations that can affect bacterial growing. Proteins produced and purified using the GST fusion system can be used in numerous biological applications.

5 Conclusion

This study allows optimization of *EG95NC-GST* expression using recombinant *E. coli* (BL21DE3) growth in SOC medium to produce the hydatidosis vaccine for ruminants including the genotype G1 of *Echinococcus granulosus* which represent the most prevalent genotype in Morocco. High yields of the recombinant protein were obtained in a fermentor that may reach up to 7000 sheep doses/l of culture. Purification of the antigen was possible using affinity chromatography to increase the quality of the final antigen that can be used for immunological studies and vaccine production.

Funding This work was funded by MCI animal health company.

Author Contributions MH, KT and ML initiated the study, participated in experimental design. MJ conducted the experiment. All authors participated in data analysis; interpretation of the results, MJ, MH wrote the paper and ML review it. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no competing interests.

Ethical Approval No human or animal subjects were used in this study. Declarations of ethical treatment of human subjects or animals, or consent of human subjects are therefore not applicable.

References

1. Moro P, Schantz PM (2009) Echinococcosis: a review. *Int J Infect Dis* 13(2):125–133
2. Schantz PM, Chai J, Craig PS, Eckert J, Jenkins DJ, Macpherson CNL, Thankur A (1995) Epidemiology and control of hydatid disease. In: Thompson RCA, Lymbery AJ (eds) *Echinococcus and hydatid disease*. CAB International, Wallingford
3. Hemphill A, Kern P (2008) Special issue: experimental studies in echinococcosis. *Exp Parasitol* 119:437–438
4. Ministry of Health Morocco, Direction de l'Epidémiologie et de la lutte Contre les maladies. *Service des maladies Parasitaires*, Ministry of Health Morocco, Rabat, Morocco, 2012
5. Ouhelli H, Kadiri A, El Hasnaoui M, Kachani M (1997) Prevalence of *Echinococcus granulosus* in dogs in Morocco and potential role of dogs in transmission of cystic echinococcosis. In: Anderson FL, Ouhelli H, Kachani M (eds) *Compendium on cystic echinococcosis in Africa and in middle eastern countries with special reference to Morocco*. Brigham Young University, Provo, 145–155
6. Azlaf R, Dakkak A (2006) Epidemiological study of the cystic echinococcosis in Morocco. *Vet Parasitol* 137:83–93
7. El Berbri I, Petavy AF, Umhang G, Bouslikhane M, Fassi Fihri O, Boue F, Dakkak A (2015) Epidemiological investigations

- on cystic *Echinococcosis* in North-West (Sidi Kacem province) Morocco: infection in ruminants. *Adv Epidemiol* 2015:104025
8. Lightowlers MW, Flisser A, Gauci CG, Heath DD, Jensen O, Rolfe R (2000) Vaccination against cysticercosis and hydatid disease. *Parasitol Today* 16:191–196
 9. Lightowlers MW, Lawrence SB, Gauci CG, Young J, Ralston MJ, Maas D, Heath DD (1996) Vaccination against hydatidosis using a defined recombinant antigen. *Parasite Immunol* 18:457–462
 10. Manderson D, Dempster R, Chisti Y (2006) A recombinant vaccine against hydatidosis: production of the antigen in *Escherichia coli*. *J Ind Microbiol Biotechnol* 33:173–182
 11. Lightowlers MW, Jensen O, Fernandez E, Iriarte JA, Woollard DJ, Gauci CG, Jenkins DJ, Heath DD (1999) Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep. *Int J Parasitol* 29:531–534
 12. Heath DD, Jensen O, Lightowlers MW (2003) Progress in control of hydatidosis using vaccination—a review of formulation and delivery of the vaccine and recommendations for practical use in control programmes. *Acta Trop* 85:133–143
 13. Gauci CG, Jenkins D, Lightowlers MW (2011) Strategies for optimal expression of vaccine antigens from taeniid cestode parasites in *Escherichia coli*. *Mol Biotechnol* 48:277–289
 14. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680–685
 15. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72:248–254
 16. Billman-Jacobe H, Hodgson ALM, Lightowlers M, Wood PR, Radford AJ (1994) Expression of ovine gamma interferon in *Escherichia coli* and *Corynebacterium glutamicum*. *Appl Environ Microbiol* 60:1641–1645
 17. Broedel SE Jr, Papciak SM, Jones WR (2001) The selection of optimum media formulations for improved expression of recombinant proteins in *E. coli*, vol 2. Athena Environmental Sciences, Inc., Baltimore
 18. Zanette D, Dundon W, Soffientini A, Sottani C, Marinelli F, Akeson A, Sarubbi E (1998) Human IL-1 receptor antagonist from *Escherichia coli*: large-scale microbial growth and protein purification. *J Biotechnol* 64:187–196
 19. Lim H-K, Jung K-H, Park D-H, Chung S-I (2000) Production characteristics of interferon- α using an l-arabinose promoter system in a high-cell-density culture. *Appl Microbiol Biotechnol* 53:201–208
 20. Korz DJ, Rinas U, Hellmuth K, Sanders EA, Deckwer W-D (1995) Simple fed-batch technique for high cell density cultivation of *Escherichia coli*. *J Biotechnol* 39:59–65